Advertisement

Topics

Synlogic Reports Third Quarter 2017 Financial Results and Recent Progress

16:05 EST 13 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
- Reported Positive Top-line Results from Phase 1 Clinical Study of SYNB1020 in Healthy Volunteers - - Received Orphan Drug Designation for SYNB1618, a Synthetic BioticTM Medicine for the Treatment of Phenylketonuria - ...

Other Sources for this Article

MEDIA CONTACT:
Synlogic
Courtney Heath, 617-872-2462
courtney@scientpr.com
or
INVESTOR CONTACT:
Synlogic
Elizabeth Wolffe, Ph.D., 617-207-5509
liz@synlogictx.com

NEXT ARTICLE

More From BioPortfolio on "Synlogic Reports Third Quarter 2017 Financial Results and Recent Progress"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...